سعر روكسيكام 8مجم للحقن عضل وريد فيال 2024

Rheuxicam 8 mg powder for IM/IV injection, one vial (Chemipharm, Egypt): lornoxicam, an oxicam NSAID.

• Short-term relief of acute mild to moderate pain.Population: AdultsHealth Products Regulatory Authority (HPRA), Ireland

• About 20% of patients may experience adverse reactions; most frequent are nausea, dyspepsia, indigestion, abdominal pain, vomiting and diarrhoea (generally under 10%).International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Hypersensitivity to lornoxicam or excipients; thrombocytopenia; hypersensitivity (asthma, rhinitis, angioedema, urticaria) to other NSAIDs including aspirin; severe heart failure; GI, cerebrovascular or other bleeding disorders; history of NSAID-related GI bleeding/perforation; active or recurrent peptic ulcer; severe hepatic impairment; severe renal impairment (serum creatinine >700 µmol/L); third trimester of pregnancy.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Use with careful risk-benefit assessment in mild to moderate renal impairment, coagulation disorders, hepatic impairment and in the elderly; avoid combination with other NSAIDs including COX-2 inhibitors; use the lowest effective dose for the shortest duration.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Contraindicated in the third trimester; should not be used in the first and second trimesters or during delivery because no clinical data on exposed pregnancies are available.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland
• No human data; lornoxicam is excreted in rat milk in relatively high concentrations, so it should not be used in breastfeeding women.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland